Concept Medical Unveils Promising 3-Year SIRONA Data at Charing Cross 2026 Symposium

Introduction to the SIRONA Trial

On April 28, 2026, Concept Medical Inc. announced significant preliminary findings from the SIRONA trial, with a three-year follow-up presented at the Charing Cross (CX) Symposium 2026 in London. This randomized controlled trial aims to compare sirolimus-coated balloon angioplasty against paclitaxel-coated balloon angioplasty for treating femoropopliteal disease. With outcomes showcasing strong evidence in a domain traditionally ruled by paclitaxel therapies, the SIRONA trial adds a new dimension to the treatment landscape.

Promising 3-Year Results

The findings presented by principal investigator, Professor Ulf Teichgräber, highlighted that MagicTouch PTA, a sirolimus-coated balloon, demonstrated a notably higher freedom from clinically-driven target lesion revascularization (cdTLR) in comparison to the paclitaxel-coated balloon group. Specifically, the results showed an 88.2% absence of reintervention in the sirolimus group versus 80.2% for the paclitaxel group (Hazard Ratio [HR] 0.60; 95% Confidence Interval [CI] 0.36-0.97; log-rank test p=0.03). These promising results indicate that sirolimus-coated balloon angioplasty may lead to more sustainable long-term results than its paclitaxel counterpart.

Key Safety and Efficacy Outcomes

The overall mortality rates remained consistent between the two treatment groups at three years, with both showing a 92.6% survival rate, affirming a balanced long-term safety profile. Furthermore, the rates for major amputations were exceedingly low, with no statistically significant differences between the groups (99.6% in both; HR 0.54; p=0.61). Professor Teichgräber expressed optimism about the sustained reduction in cdTLR with sirolimus treatment over such an extended follow-up period, noting this as a significant milestone for drug-eluting technologies in femoropopliteal interventions.

The Future of Sirolimus Coated Balloons

The exploratory results from the SIRONA trial signal a potential shift in the landscape of peripheral artery disease treatment. It emphasizes the importance of evaluating various sirolimus-eluting balloon technologies based on robust clinical evidence rather than assuming a class effect. Dr. Manish Doshi, the founder and CEO of Concept Medical, emphasized the importance of ongoing data generation to inform clinicians confidently as they incorporate these innovative therapeutic options into practice.

Conclusion

As the medical community looks toward future advancements in vascular intervention, the SIRONA trial's preliminary findings present compelling evidence for the long-term benefits of sirolimus-coated balloons. Concept Medical continues to position itself at the forefront of medical technology, striving to deliver high-quality, reliable solutions that can make a meaningful impact on patient care and outcomes. With further assessments pending a decision from the Clinical Events Committee (CEC), the anticipation surrounding these findings highlights a critical moment for the broader medical field.

Through rigorous clinical trials like SIRONA, Concept Medical aims to establish a scientifically grounded foundation for developing innovative treatments that enhance vascular health and improve patient outcomes across the globe.